The shareholders of Lipum are invited to the Annual General Meeting on June 16, 2025, at 1:00 PM at Lipum’s office, Tvistevägen 48C, 907 36 Umeå.

The annual report is available on the company’s website (only in Swedish).

In the annual report, CEO Ola Sandborgh comments: "With 2024 behind us, I can proudly state that it has been a very successful year for Lipum. We have achieved several important milestones, made significant progress in our drug development, and at the same time strengthened both our scientific position and financial foundation. Above all, we have received clear evidence that our research is delivering results – and that it is well worth supporting."

Contacts
Ola Sandborgh, CEO
ola.sandborgh@lipum.se
+46 72 218 80 21
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical phase with a successfully completed Phase 1 study. Together with strong preclinical data, we have a solid foundation for continued development in the treatment of rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments
Lipum AB 2024 Arsredovisning

Lipum AB 2024 Arsredovisning